Cargando…

An immune indicator based on BTK and DPEP2 identifies hot and cold tumors and clinical treatment outcomes in lung adenocarcinoma

In lung adenocarcinoma (LUAD), immune heterogeneity of hot and cold tumors has been recognized as one of the major factors affecting immunotherapy and other common treatments. However, there is still a lack of biomarkers that can effectively identify the immunophenotype of cold and hot tumors. First...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Tao, Liu, Yafeng, Wu, Jing, Bai, Ying, Zhou, Jiawei, Hu, Chunxiao, Zhang, Wenting, Guo, Jianqiang, Wang, Qingsen, Hu, Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060209/
https://www.ncbi.nlm.nih.gov/pubmed/36991102
http://dx.doi.org/10.1038/s41598-023-32276-2
_version_ 1785017050971766784
author Han, Tao
Liu, Yafeng
Wu, Jing
Bai, Ying
Zhou, Jiawei
Hu, Chunxiao
Zhang, Wenting
Guo, Jianqiang
Wang, Qingsen
Hu, Dong
author_facet Han, Tao
Liu, Yafeng
Wu, Jing
Bai, Ying
Zhou, Jiawei
Hu, Chunxiao
Zhang, Wenting
Guo, Jianqiang
Wang, Qingsen
Hu, Dong
author_sort Han, Tao
collection PubMed
description In lung adenocarcinoma (LUAD), immune heterogeneity of hot and cold tumors has been recognized as one of the major factors affecting immunotherapy and other common treatments. However, there is still a lack of biomarkers that can effectively identify the immunophenotype of cold and hot tumors. First, the immune signatures were obtained based on literature mining, including macrophage/monocyte, IFN-γ response, TGF-β response, IL12 response, lymphocyte activation, and ECM/Dve/immune response. Subsequently, LUAD patients were further clustered into different immune phenotypes based on these immune signatures. Next, the key genes related to the immune phenotypes were screened by WGCNA analysis, univariate analysis, and lasso-cox analysis, and the risk signature was established via the key genes. In additional, we compared the clinicopathological characteristics, drug sensitivity, the abundance of immune infiltration, and the efficacy of immunotherapy and commonly used therapies between patients in the high- and low-risk groups in LUAD. LUAD patients were divided into immune hot phenotype and immune cold phenotype groups. The clinical presentation showed that patients with the immune hot phenotype had higher immunoactivity (including higher MHC, CYT, immune, stromal, ESTIMATE scores, higher abundance of immune cell infiltration, higher abundance of TIL, and enrichment of immune-enriched subtypes) and better survival outcomes than those with the immune cold phenotype. Subsequently, WGCNA analysis, univariate analysis, and lasso-cox analysis identified the genes highly associated with the immune phenotype: BTK and DPEP2. The risk signature, consisting of BTK and DPEP2, is highly correlated with the immune phenotype. High-risk scores were enriched in patients with immune cold phenotype and low-risk scores were enriched in patients with immune hot phenotype. Compared to the high-risk group, the low-risk group had better clinical performance, higher drug sensitivity, and a higher degree of immunoactivity, as well as better efficacy in receiving immunotherapy and common adjuvant therapy. This study developed an immune indicator consisting of BTK and DPEP2 based on the heterogeneity of hot and cold Immunophenotypes of the tumor microenvironment. This indicator has good efficacy in predicting prognosis and assessing the efficacy of immunotherapy, chemotherapy, and radiotherapy. It has the potential to facilitate personalized and precise treatment of LUAD in the future.
format Online
Article
Text
id pubmed-10060209
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-100602092023-03-31 An immune indicator based on BTK and DPEP2 identifies hot and cold tumors and clinical treatment outcomes in lung adenocarcinoma Han, Tao Liu, Yafeng Wu, Jing Bai, Ying Zhou, Jiawei Hu, Chunxiao Zhang, Wenting Guo, Jianqiang Wang, Qingsen Hu, Dong Sci Rep Article In lung adenocarcinoma (LUAD), immune heterogeneity of hot and cold tumors has been recognized as one of the major factors affecting immunotherapy and other common treatments. However, there is still a lack of biomarkers that can effectively identify the immunophenotype of cold and hot tumors. First, the immune signatures were obtained based on literature mining, including macrophage/monocyte, IFN-γ response, TGF-β response, IL12 response, lymphocyte activation, and ECM/Dve/immune response. Subsequently, LUAD patients were further clustered into different immune phenotypes based on these immune signatures. Next, the key genes related to the immune phenotypes were screened by WGCNA analysis, univariate analysis, and lasso-cox analysis, and the risk signature was established via the key genes. In additional, we compared the clinicopathological characteristics, drug sensitivity, the abundance of immune infiltration, and the efficacy of immunotherapy and commonly used therapies between patients in the high- and low-risk groups in LUAD. LUAD patients were divided into immune hot phenotype and immune cold phenotype groups. The clinical presentation showed that patients with the immune hot phenotype had higher immunoactivity (including higher MHC, CYT, immune, stromal, ESTIMATE scores, higher abundance of immune cell infiltration, higher abundance of TIL, and enrichment of immune-enriched subtypes) and better survival outcomes than those with the immune cold phenotype. Subsequently, WGCNA analysis, univariate analysis, and lasso-cox analysis identified the genes highly associated with the immune phenotype: BTK and DPEP2. The risk signature, consisting of BTK and DPEP2, is highly correlated with the immune phenotype. High-risk scores were enriched in patients with immune cold phenotype and low-risk scores were enriched in patients with immune hot phenotype. Compared to the high-risk group, the low-risk group had better clinical performance, higher drug sensitivity, and a higher degree of immunoactivity, as well as better efficacy in receiving immunotherapy and common adjuvant therapy. This study developed an immune indicator consisting of BTK and DPEP2 based on the heterogeneity of hot and cold Immunophenotypes of the tumor microenvironment. This indicator has good efficacy in predicting prognosis and assessing the efficacy of immunotherapy, chemotherapy, and radiotherapy. It has the potential to facilitate personalized and precise treatment of LUAD in the future. Nature Publishing Group UK 2023-03-29 /pmc/articles/PMC10060209/ /pubmed/36991102 http://dx.doi.org/10.1038/s41598-023-32276-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Han, Tao
Liu, Yafeng
Wu, Jing
Bai, Ying
Zhou, Jiawei
Hu, Chunxiao
Zhang, Wenting
Guo, Jianqiang
Wang, Qingsen
Hu, Dong
An immune indicator based on BTK and DPEP2 identifies hot and cold tumors and clinical treatment outcomes in lung adenocarcinoma
title An immune indicator based on BTK and DPEP2 identifies hot and cold tumors and clinical treatment outcomes in lung adenocarcinoma
title_full An immune indicator based on BTK and DPEP2 identifies hot and cold tumors and clinical treatment outcomes in lung adenocarcinoma
title_fullStr An immune indicator based on BTK and DPEP2 identifies hot and cold tumors and clinical treatment outcomes in lung adenocarcinoma
title_full_unstemmed An immune indicator based on BTK and DPEP2 identifies hot and cold tumors and clinical treatment outcomes in lung adenocarcinoma
title_short An immune indicator based on BTK and DPEP2 identifies hot and cold tumors and clinical treatment outcomes in lung adenocarcinoma
title_sort immune indicator based on btk and dpep2 identifies hot and cold tumors and clinical treatment outcomes in lung adenocarcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060209/
https://www.ncbi.nlm.nih.gov/pubmed/36991102
http://dx.doi.org/10.1038/s41598-023-32276-2
work_keys_str_mv AT hantao animmuneindicatorbasedonbtkanddpep2identifieshotandcoldtumorsandclinicaltreatmentoutcomesinlungadenocarcinoma
AT liuyafeng animmuneindicatorbasedonbtkanddpep2identifieshotandcoldtumorsandclinicaltreatmentoutcomesinlungadenocarcinoma
AT wujing animmuneindicatorbasedonbtkanddpep2identifieshotandcoldtumorsandclinicaltreatmentoutcomesinlungadenocarcinoma
AT baiying animmuneindicatorbasedonbtkanddpep2identifieshotandcoldtumorsandclinicaltreatmentoutcomesinlungadenocarcinoma
AT zhoujiawei animmuneindicatorbasedonbtkanddpep2identifieshotandcoldtumorsandclinicaltreatmentoutcomesinlungadenocarcinoma
AT huchunxiao animmuneindicatorbasedonbtkanddpep2identifieshotandcoldtumorsandclinicaltreatmentoutcomesinlungadenocarcinoma
AT zhangwenting animmuneindicatorbasedonbtkanddpep2identifieshotandcoldtumorsandclinicaltreatmentoutcomesinlungadenocarcinoma
AT guojianqiang animmuneindicatorbasedonbtkanddpep2identifieshotandcoldtumorsandclinicaltreatmentoutcomesinlungadenocarcinoma
AT wangqingsen animmuneindicatorbasedonbtkanddpep2identifieshotandcoldtumorsandclinicaltreatmentoutcomesinlungadenocarcinoma
AT hudong animmuneindicatorbasedonbtkanddpep2identifieshotandcoldtumorsandclinicaltreatmentoutcomesinlungadenocarcinoma
AT hantao immuneindicatorbasedonbtkanddpep2identifieshotandcoldtumorsandclinicaltreatmentoutcomesinlungadenocarcinoma
AT liuyafeng immuneindicatorbasedonbtkanddpep2identifieshotandcoldtumorsandclinicaltreatmentoutcomesinlungadenocarcinoma
AT wujing immuneindicatorbasedonbtkanddpep2identifieshotandcoldtumorsandclinicaltreatmentoutcomesinlungadenocarcinoma
AT baiying immuneindicatorbasedonbtkanddpep2identifieshotandcoldtumorsandclinicaltreatmentoutcomesinlungadenocarcinoma
AT zhoujiawei immuneindicatorbasedonbtkanddpep2identifieshotandcoldtumorsandclinicaltreatmentoutcomesinlungadenocarcinoma
AT huchunxiao immuneindicatorbasedonbtkanddpep2identifieshotandcoldtumorsandclinicaltreatmentoutcomesinlungadenocarcinoma
AT zhangwenting immuneindicatorbasedonbtkanddpep2identifieshotandcoldtumorsandclinicaltreatmentoutcomesinlungadenocarcinoma
AT guojianqiang immuneindicatorbasedonbtkanddpep2identifieshotandcoldtumorsandclinicaltreatmentoutcomesinlungadenocarcinoma
AT wangqingsen immuneindicatorbasedonbtkanddpep2identifieshotandcoldtumorsandclinicaltreatmentoutcomesinlungadenocarcinoma
AT hudong immuneindicatorbasedonbtkanddpep2identifieshotandcoldtumorsandclinicaltreatmentoutcomesinlungadenocarcinoma